Qingsong Pang
Overview
Explore the profile of Qingsong Pang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
106
Citations
1548
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang K, Wang Q, Cao J, Fan C, Shen W, Xiao Q, et al.
BMC Cancer
. 2025 Feb;
25(1):347.
PMID: 40001034
Background: The standard treatment for elderly patients with unresectable locally advanced esophageal squamous cell carcinoma (ESCC) is definitive chemoradiotherapy with S-1. However, the 3-year overall survival (OS) is limited to...
2.
Zhao F, Wang Q, Han W, Maitudi W, Cao F, Zhang T, et al.
Cancer Med
. 2025 Feb;
14(4):e70676.
PMID: 39945301
Background: The recurrence patterns of different types of pathologic regression of the primary tumor and lymph nodes in patients with esophageal squamous cell carcinoma (ESCC) after neoadjuvant chemoradiotherapy (NCRT) are...
3.
Lv X, Wang S, Zhang W, Pang Q, Lin Q, Wu Y, et al.
Strahlenther Onkol
. 2025 Jan;
PMID: 39805975
Purpose: To evaluate the safety and efficacy of radiotherapy combined with chemoimmunotherapy (RCIT) versus chemoimmunotherapy (CIT) alone as first-line treatment for oligometastatic esophageal squamous cell carcinoma (OESCC) at initial diagnosis....
4.
Xu Y, Lin C, Han C, Wang X, Zhao Y, Pang Q, et al.
BMC Cancer
. 2025 Jan;
25(1):40.
PMID: 39780142
Background: Our goal is to develop a nomogram model to predict overall survival (OS) for elderly esophageal squamous cell carcinoma (ESCC) patients receiving definitive radiotherapy (RT) or concurrent chemoradiotherapy (CRT),...
5.
Li J, Wang X, Cao J, Fan C, Xiao Q, Zheng Z, et al.
Cancer Lett
. 2024 Dec;
611:217411.
PMID: 39736452
Immunochemotherapy is Currently the standard first-line treatment for advanced esophageal squamous cell carcinoma (ESCC). However, its prognosis remains unsatisfactory. We aimed to evaluate the efficacy and safety of immunochemotherapy plus...
6.
Liu Y, Wang Y, Hu X, Wang X, Xue L, Pang Q, et al.
Insights Imaging
. 2024 Nov;
15(1):277.
PMID: 39546168
Objectives: This study aimed to develop and validate a deep-learning radiomics model using CT, T2, and DWI images for predicting pathological complete response (pCR) in patients with esophageal squamous cell...
7.
Dong B, Chen L, Pang Q, Jiang O, Ge H, Cheng Y, et al.
Transl Lung Cancer Res
. 2024 Nov;
13(10):2828-2837.
PMID: 39507039
Background: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of non-small cell lung cancer (NSCLC). TQB2450 (benmelstobart) is a novel humanized immunoglobulin G1 monoclonal antibody against programmed death-ligand 1 (PD-L1)....
8.
Zheng J, Zheng Z, Zhang T, Chen X, Pang Q, Wang P, et al.
Expert Opin Biol Ther
. 2024 Oct;
24(11):1221-1232.
PMID: 39460561
Introduction: Locally advanced esophageal cancer (EC) has poor prognosis. Preliminary clinical studies have demonstrated the synergistic efficacy of radiotherapy combined with immunotherapy in EC. Adjusting the radiotherapy target volume to...
9.
Wu L, Li B, Wan G, Wang Y, Zhu J, Liang L, et al.
Nat Commun
. 2024 Aug;
15(1):7116.
PMID: 39164237
This single-arm phase 2 trial (ChiCTR2100046715) examined previously untreated patients with advanced esophageal squamous cell carcinoma (ESCC) who received four cycles of paclitaxel with carboplatin every 3 weeks. Toripalimab was...
10.
Zhang J, Li M, Zhang K, Zheng A, Li G, Huang W, et al.
Cancer Commun (Lond)
. 2024 Aug;
44(10):1173-1188.
PMID: 39161079
Background: Concurrent chemoradiotherapy (CCRT) is the standard treatment for locally advanced esophageal squamous cell carcinoma (ESCC). However, the optimal radiotherapy regimen, particularly in terms of total dose and planned range...